We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
AstraZeneca announced it will buy the remaining shares of UK-based Cambridge Antibody Technology Group (CAT) for just over the equivalent of $1.07 billion.
Smaller public companies — including many biotechnology firms — face disproportionately higher costs as a percentage of revenue to meet the internal control requirements of Sarbanes-Oxley (SOX) than do their larger counterparts, according to a study by the Government Accountability Office (GAO).
Swiss biopharmaceuticals company Biopartners has received authorization to market its recombinant growth hormone Valtropin in the European Union (EU), the company said May 4.
An SEC advisory committee has overwhelmingly recommended that the agency grant relief from Sarbanes-Oxley (SOX) reporting and auditing requirements for small companies, but the panel does not have the influence on the SEC that the pharmaceutical and biotechnology industries may believe, an agency spokesman says.
The European Commission (EC) has granted Sandoz marketing authorization for its recombinant human growth hormone Omnitrope that will be the first biosimilar to be marketed after being approved under the EC’s biosimilar pathway.
The emerging biotechnology market, ranging from anti-inflammatory medications to cardiovascular and cancer therapies, stands to benefit from the needs of an aging Baby Boomer generation comprising nearly one-third of the U.S. population, a recent study finds.
Price controls discourage the development of second-generation brand drugs, according to a report issued April 13 by the American Enterprise Institute-Brookings Joint Center.
From anti-inflammatory medications to cardiovascular and cancer therapies, the emerging biotechnology market stands to benefit from the needs of an aging Baby Boomer generation comprising nearly one-third of the U.S. population, concludes a recent study.
Bayer will bid to acquire Schering AG after that company's executive board rejected a takeover offer from Merck KGaA, according to the three companies.